These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 23449602)

  • 1. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.
    Black SW; Morairty SR; Fisher SP; Chen TM; Warrier DR; Kilduff TS
    Sleep; 2013 Mar; 36(3):325-36. PubMed ID: 23449602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locus Coeruleus and Tuberomammillary Nuclei Ablations Attenuate Hypocretin/Orexin Antagonist-Mediated REM Sleep.
    Schwartz MD; Nguyen AT; Warrier DR; Palmerston JB; Thomas AM; Morairty SR; Neylan TC; Kilduff TS
    eNeuro; 2016; 3(2):. PubMed ID: 27022631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy.
    Black SW; Morairty SR; Chen TM; Leung AK; Wisor JP; Yamanaka A; Kilduff TS
    J Neurosci; 2014 May; 34(19):6485-94. PubMed ID: 24806675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypocretin/orexin antagonism enhances sleep-related adenosine and GABA neurotransmission in rat basal forebrain.
    Vazquez-DeRose J; Schwartz MD; Nguyen AT; Warrier DR; Gulati S; Mathew TK; Neylan TC; Kilduff TS
    Brain Struct Funct; 2016 Mar; 221(2):923-40. PubMed ID: 25431268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs.
    John J; Wu MF; Siegel JM
    Sleep Res Online; 2000; 3(1):23-8. PubMed ID: 11382896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parallel Arousal Pathways in the Lateral Hypothalamus.
    Heiss JE; Yamanaka A; Kilduff TS
    eNeuro; 2018; 5(4):. PubMed ID: 30225361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors.
    Mang GM; Dürst T; Bürki H; Imobersteg S; Abramowski D; Schuepbach E; Hoyer D; Fendt M; Gee CE
    Sleep; 2012 Dec; 35(12):1625-35. PubMed ID: 23204605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy.
    Baier PC; Hallschmid M; Seeck-Hirschner M; Weinhold SL; Burkert S; Diessner N; Göder R; Aldenhoff JB; Hinze-Selch D
    Sleep Med; 2011 Dec; 12(10):941-6. PubMed ID: 22036605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex-related differences within sleep-wake dynamics, cataplexy, and EEG fast-delta power in a narcolepsy mouse model.
    Piilgaard L; Rose L; Gylling Hviid C; Kohlmeier KA; Kornum BR
    Sleep; 2022 Jul; 45(7):. PubMed ID: 35266540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specificity of direct transition from wake to REM sleep in orexin/ataxin-3 transgenic narcoleptic mice.
    Fujiki N; Cheng T; Yoshino F; Nishino S
    Exp Neurol; 2009 May; 217(1):46-54. PubMed ID: 19416673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sleep and cardiovascular phenotype in middle-aged hypocretin-deficient narcoleptic mice.
    Silvani A; Bastianini S; Berteotti C; Cenacchi G; Leone O; Lo Martire V; Papa V; Zoccoli G
    J Sleep Res; 2014 Feb; 23(1):98-106. PubMed ID: 24033681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgenic Archaerhodopsin-3 Expression in Hypocretin/Orexin Neurons Engenders Cellular Dysfunction and Features of Type 2 Narcolepsy.
    Williams RH; Tsunematsu T; Thomas AM; Bogyo K; Yamanaka A; Kilduff TS
    J Neurosci; 2019 Nov; 39(47):9435-9452. PubMed ID: 31628177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of hypocretin attenuates behavioral changes produced by glutamatergic activation of the perifornical-lateral hypothalamic area.
    Kostin A; Siegel JM; Alam MN
    Sleep; 2014 May; 37(5):1011-20. PubMed ID: 24790280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function.
    Tabuchi S; Tsunematsu T; Black SW; Tominaga M; Maruyama M; Takagi K; Minokoshi Y; Sakurai T; Kilduff TS; Yamanaka A
    J Neurosci; 2014 May; 34(19):6495-509. PubMed ID: 24806676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of hypocretin (orexin) deficiency in hypocretin/ataxin-3 transgenic rats.
    Zhang S; Lin L; Kaur S; Thankachan S; Blanco-Centurion C; Yanagisawa M; Mignot E; Shiromani PJ
    Neuroscience; 2007 Aug; 148(1):34-43. PubMed ID: 17618058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Dual Hypocretin Receptor Antagonist Almorexant is Permissive for Activation of Wake-Promoting Systems.
    Parks GS; Warrier DR; Dittrich L; Schwartz MD; Palmerston JB; Neylan TC; Morairty SR; Kilduff TS
    Neuropsychopharmacology; 2016 Mar; 41(4):1144-55. PubMed ID: 26289145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypocretin (orexin) is critical in sustaining theta/gamma-rich waking behaviors that drive sleep need.
    Vassalli A; Franken P
    Proc Natl Acad Sci U S A; 2017 Jul; 114(27):E5464-E5473. PubMed ID: 28630298
    [No Abstract]   [Full Text] [Related]  

  • 18. Non-invasive detection of narcolepsy type I phenotypical features and disease progression by continuous home-cage monitoring of activity in two mouse models: the HCRT-KO and DTA model.
    Piilgaard L; Rose L; Justinussen JL; Hviid CG; Lemcke R; Wellendorph P; Kornum BR
    Sleep; 2023 Sep; 46(9):. PubMed ID: 37210587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypocretin-2 saporin lesions of the ventrolateral periaquaductal gray (vlPAG) increase REM sleep in hypocretin knockout mice.
    Kaur S; Thankachan S; Begum S; Liu M; Blanco-Centurion C; Shiromani PJ
    PLoS One; 2009 Jul; 4(7):e6346. PubMed ID: 19623260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive detection of sleep/wake changes and cataplexy-like behaviors in orexin/ataxin-3 transgenic narcoleptic mice across the disease onset.
    Sato M; Sagawa Y; Hirai N; Sato S; Okuro M; Kumar S; Kanbayashi T; Shimizu T; Sakai N; Nishino S
    Exp Neurol; 2014 Nov; 261():744-51. PubMed ID: 25118620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.